Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer

October 3rd 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Expert Discusses Optimizing Sequence of Non-Hormonal Therapy in mCRPC

October 3rd 2017

Daniel J. George, MD, discusses the major questions practitioners are asking regarding optimizing upfront therapy for patients with mCRPC.

Dr. Aggarwal on Androgen Deprivation Therapy for Prostate Cancer

September 29th 2017

Rahul Aggarwal, MD, assistant professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Comprehensive Cancer Center, discusses androgen deprivation therapy for patients with prostate cancer.

PSMA-PET Agents Poised to Advance Imaging in Prostate Cancer

September 27th 2017

Thomas Hope, MD, discusses the novel technique PSMA-PET and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.

Pivotal Role Remains With Bone-Targeting Agents in mCRPC

September 27th 2017

Charles Ryan, MD, discusses the evolution of zoledronic acid and denosumab, and the future role of radium-223 as it begins to be studied in combination regimens in prostate cancer.

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

September 26th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Expert Talks Optimizing ADT in Prostate Cancer

September 22nd 2017

Rahul Aggarwal, MD, discussed the success of recent studies of androgen-deprivation therapy in prostate cancer, as well as its future utilization in various stages of disease.

Use of Active Surveillance Increasing for Low-Risk Prostate Cancer

September 21st 2017

Matthew R. Cooperberg, MD, discusses the benefits associated with active surveillance for patients with low-risk prostate cancer, as well as the development of personalized medicine.

MFS Strong Surrogate Endpoint in Localized Prostate Cancer

September 20th 2017

After a median of 10 years’ follow-up, investigators with the ICECaP Working Group have concluded that there is a strong correlation between metastasis-free survival and overall survival in patients with localized prostate cancer.

New Standard in Metastatic Prostate Cancer Hits Prime Time

September 19th 2017

Although there have improvements in the treatment of men with prostate cancer during the past 15 years, patients with advanced disease continue to pose a clinical challenge.

FDA Approves Reduced Dose of Cabazitaxel for mCRPC

September 18th 2017

The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

September 15th 2017

A supplemental new drug application has been submitted for abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk men with castration-sensitive metastatic prostate cancer.

PROSTVAC Misses Phase III Goal in Prostate Cancer

September 15th 2017

PROSTVAC with or without GM-CSF was deemed unlikely to demonstrate an improvement in overall survival compared with placebo for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Enzalutamide Succeeds in Phase III Nonmetastatic CRPC Trial

September 14th 2017

Adding enzalutamide to androgen deprivation therapy (ADT) significantly improved metastasis-free survival versus ADT alone in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III PROSPER trial.

Dr. Choyke on the Importance of Multidisciplinary Care in Prostate Cancer

September 8th 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the importance of multidisciplinary care in prostate cancer.

Dr. Hu on Active Surveillance for Prostate Cancer

September 8th 2017

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses active surveillance for patients with prostate cancer.

AKT Inhibitor May Promote Better Responses to Abiraterone in mCRPC

September 7th 2017

Ipatasertib is being investigated in patients with metastatic castration-resistant prostate cancer as a method of simultaneously blocking a resistance mechanism to hormone therapy and improving responses to abiraterone.

Dr. Feldman on Study of Active Surveillance in Younger Men With Prostate Cancer

September 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses a study of active surveillance in younger men with prostate cancer.

Dr. Brawer on the Results of the Prolaris Test for Patients Prostate Cancer

September 6th 2017

Michael Brawer, MD, vice president of medical affairs, Myriad Genetic Laboratories, discusses the results of the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate Cancer

September 1st 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.